# US 2021/0171936 A1 · Antibody libraries with maximized antibody developability characteristics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171936 A1
- Document ID: US20210171936A1
- Status: Published application
- Kind: A1
- Application number: 17/163,170
- Filed: 2021-01-29
- Published: 2021-06-10
- Earliest claimed: 2018-07-08
- Assignees: Specifica Inc.
- Applicants: Specifica Inc.
- Inventors: Andrew Raymon Morton BRADBURY; Michael Frank ERASMUS; Andre TEIXEIRA
- Web page: https://patentgrep.com/patent/US20210171936A1

## CPC

- C40B 40/10: Libraries containing peptides or polypeptides, or derivatives thereof
- C07K 16/005: {constructed by phage libraries}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/81: for yeasts
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C07K 2317/21: from primates, e.g. man
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Antibody libraries comprising a plurality of heavy chain variable domains and/or a plurality of light chain variable domains, which comprise complementary determining regions (CDRs) found in naturally-occurring human antibodies, and methods of making such antibody libraries. The antibody libraries are free of members that comprise one or more liabilities affecting one or more features of such members. Further, the antibody libraries comprise members having heavy chain and/or light chain CDRs not found in the same naturally-occurring human antibody.

## Claims

### Claim 1

A method for producing an antibody library, comprising:
providing (a) a first plurality of nucleic acids encoding a population of naturally-occurring antibody heavy chain complementary determining region 1 (CDR1) fragments, and/or (b) a second plurality of nucleic acids encoding a population of naturally-occurring antibody heavy chain complementary determining region 2 (CDR2) fragments; and
inserting the first plurality of nucleic acids and/or the second plurality of nucleic acids into the CDR1 region and/or the CDR2 region, respectively, of an antibody heavy chain variable domain gene, thereby producing an antibody library.

### Claim 2 (depends on 1)

The method of claim 1, wherein the antibody library comprises members, in each of which the heavy chain CDR1 and heavy chain CDR2 are not from the same naturally-occurring antibody.

### Claim 3 (depends on 2)

The method of claim 2, wherein at least 50% of the members in the antibody library contain heavy chain CDR1 and heavy chain CDR2 that are not from the same naturally-occurring antibody.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, further comprising providing a third plurality of nucleic acids encoding a population of naturally-occurring heavy chain complementary determining region 3 (CDR3) fragments, and inserting the third plurality of nucleic acids into the CDR3 region of the heavy chain variable region gene.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the antibody library comprises members, each of which comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3 that are not from the same naturally-occurring antibody.

### Claim 6 (depends on 5)

The method of claim 5, wherein at least 50% of the members in the antibody library contain heavy chain CDR1, heavy chain CDR2, and/or heavy chain CDR3 that are not from the same naturally-occurring antibody.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the population of antibody heavy chain CDR1 fragments, the population of antibody heavy chain CDR2 fragments, and/or the population of antibody heavy chain CDR3 fragments is free of members comprising one or more of:
(i) a glycosylation site,
(ii) a deamidation site,
(iii) an isomerization site,
(iv) unpaired cysteine,
(v) net charge greater than 1,
(vi) a tripeptide motif containing at least two aromatic residues,
(vii) a motif that promotes aggregation,
(viii) a polyspecificity site;
(ix) a protease sensitive site,
(x) an integrin binding site,
(xi) a lysine glycation site,
(xii) a metal catalyzed fragmentation site,
(xiii) a polyspecificity aggregation site; and
(xiv) a streptavidin binding motif.

### Claim 8 (depends on 7)

The method of claim 7, wherein the glycosylation site of (i) comprises the motif NXS, NXT, or NXC, in which X represents any naturally-occurring amino acid residue except for proline.

### Claim 9 (depends on 7, 8)

The method of claim 7 or claim 8, wherein the deamidation site of (ii) comprises the motif of NG, NS, NT, NN, NA, NH, ND, GNF, GNY, GNT, or GNG.

### Claim 10 (depends on 7, 8, 9)

The method of any one of claims 7-9, wherein the isomerization site of (iii) comprises the motif of DT, DH, DS, DG, or DD.

### Claim 11 (depends on 7, 8, 9, 10)

The method of any one of claims 7-10, wherein the tripeptide of (vi) is HYF or HWH.

### Claim 12 (depends on 7, 8, 9, 10, 11)

The method of any one of claims 7-11, wherein the motif that promotes aggregation of (vii) comprises the motif of FHW.

### Claim 13 (depends on 7, 8, 9, 10, 11, 12)

The method of any one of claims 7-12, wherein the polyspecificity site of (viii) comprises the motif GG, GGG, RR, VG, W, WV, WW, WWW, YY, or WXW, in which X represents any amino acid residue.

### Claim 14 (depends on 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 7-13, wherein the protease cleavage site of (ix) comprises the motif of DX, in which X is P, G, S, V, Y, F, Q, K, L, or D.

### Claim 15 (depends on 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 7-14, wherein the integrin binding site of (x) comprises RGD, RYD, LDV, or KGD.

### Claim 16 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 7-15, wherein the lysine glycation site of (xi) comprises KE, EK, or ED.

### Claim 17 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 7-16, wherein the metal catalyzed fragmentation site of (xii) comprises the motif of HS, SH, KT, HXS, or SXH, in which X represents any amino acid residue.

### Claim 18 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 7-17, wherein the polyspecificity aggregation site of (xiii) comprises a motif of X1X2X3, wherein each of X1, X2, and X3 independently is selected from the group consisting of F, I, L, V, W and Y.

### Claim 19 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 7-18, wherein the streptavidin binding motif of (xiv) comprises the motif HPQ, EPDW (SEQ ID NO: 117), PWXWL (SEQ ID NO: 118), in which X represents any amino acid residue, GDWVFI (SEQ ID NO: 119), or PWPWLG (SEQ ID NO: 120).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the population of antibody heavy chain CDR1 fragments, the population of antibody heavy chain CDR2 fragments, and/or the population of antibody heavy chain CDR3 fragments is free of members comprising at least two of (i)-(xiv).

### Claim 21 (depends on 20)

The method of claim 20, wherein the population of antibody heavy chain CDR1 fragments, the population of antibody heavy chain CDR2 fragments, and/or the population of antibody heavy chain CDR3 fragments is free of members comprising (i)-(ix).

### Claim 22 (depends on 21)

The method of claim 21, wherein the population of antibody heavy chain CDR1 fragments, the population of antibody heavy chain CDR2 fragments, and/or the population of antibody heavy chain CDR3 fragment is further free of members comprising one or more of (x)-(xiv).

### Claim 23 (depends on 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 7-22, wherein the first plurality of nucleic acid is produced by a process comprising:
(a) obtaining amino acid sequences of the heavy chain CDR1 regions of a population of naturally-occurring antibodies,
(b) excluding from (a) the heavy chain CDR1 amino acid sequences that comprise one or more of (i) to (xiv) to obtain liability-free heavy chain CDR1 sequences, and
(c) synthesizing the first plurality of nucleic acids that encode the liability-free heavy chain CDR1 regions.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the second plurality of nucleic acid is produced by a process comprising:
(a) obtaining amino acid sequences of the heavy chain CDR2 regions of a population of naturally-occurring antibodies,
(b) excluding from (a) the heavy chain CDR2 amino acid sequences that comprise one or more of (i) to (xiv) to obtain liability-free heavy chain CDR2 sequences, and
(c) synthesizing the second plurality of nucleic acids that encode the liability-free heavy chain CDR2 regions.

### Claim 25 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 3-24, wherein the third plurality of nucleic acids is produced by a process comprising:
(a) obtaining amino acid sequences of the heavy chain CDR3 regions of a population of naturally-occurring antibodies,
(b) excluding from (a) the heavy chain CDR3 amino acid sequences that comprise one or more of (i) to (xiv) to obtain liability-free heavy chain CDR3 sequences, and
(c) synthesizing the second plurality of nucleic acids that encode the liability-free heavy chain CDR3 regions.

### Claim 26 (depends on 20, 21, 22, 23, 24, 25)

The method of claims 20-25, wherein the process for producing the first, second, and/or third plurality of nucleic acids further comprises, after step (c), isolating functional members from the liability-free heavy chain CDR1, CDR2, and/or CDR3 regions.

### Claim 27 (depends on 26)

The method of claim 26, wherein the functional members of the liability-free heavy chain CDR1, CDR2, and/or CDR3 are isolated by expressing antibodies comprising the liability-free heavy chain CDR1, CDR2, and/or CDR3 regions in host cells in a manner that the antibodies are displayed on surface of the host cells, isolating the antibodies that display on the host cells, and identifying the CDR1, CDR2, and/or CDR3 regions in the displayed antibodies, which are functional members of the liability-free heavy chain CDR1, CDR2, and/or CDR3 regions.

### Claim 28 (depends on 27)

The method of claim 27, wherein the isolated antibodies that display on the host cells show reduced binding to polyspecificity reagents.

### Claim 29 (depends on 26)

The method of claim 26, wherein the functional members of the liability-free heavy chain CDR1, CDR2, and/or CDR3 are isolated by expressing antibodies comprising the liability-free heavy chain CDR1, CDR2, and/or CDR3 regions in fusion with a folding reporter, which optionally is 13 lactamase or green fluorescent protein, or fragments thereof, to obtain members with improved folding.

### Claim 30 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 4-29, wherein the population of human antibody heavy chain CDR3 fragments is derived from B cells.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the antibody heavy chain variable region gene is a human heavy chain variable region gene, which optionally is selected from the group consisting of VH1-24, VH2-70, VH3-7, VH4-30-4, VH5-51, VH1-18, VH1-69, VH3-23, VH5-10-1, VH3-9, and VH3-11.

### Claim 32 (depends on 31)

The method of claim 31, wherein the human antibody heavy chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abrilumab, mepolizumab, crenezumab, necitumumab, anifrolumab, and evoculumab.

### Claim 33 (depends on 31)

The method of claim 31, wherein the human antibody heavy chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abituzumab, adalimumab, alemtuzumab, alirocumab, bapineuzumab, benralizumab, brodalumab, canakinumab, certolizumab, clazakizumab, dacetuzumab, daclizumab, daratumumab, eculizumab, efalizumab, elotuzumab, epratuzumab, farletuzumab, fasinumab, ficlatuzumab, fletikumab, fresolimumab, fulranumab, gevokizumab, ibalizumab, lintuzumab, matuzumab, mavrilimumab, mogamulizumab, motavizumab, natalizumab, nivolumab, obinutuzumab, ofatumumab, olokizumab, omalizumab, onartuzumab, otelixizumab, otlertuzumab, palivizumab, panitumumab, panobacumab, pertuzumab, pinatuzumab, polatuzumab, radretumab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sifalimumab, tabalumab, tigatuzumab, tildrakizumab, tocilizumab, tovetumab, trastuzumab, vedolizumab, veltuzumab, zalutumumab, and zanolimumab.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the method further comprises:
providing a fourth plurality of nucleic acids encoding a population of naturally-occurring antibody light chain complementary determining region 1 (CDR1) fragments, a fifth plurality of nucleic acids encoding a population of naturally-occurring antibody light chain complementary determining region 2 (CDR2) fragments, and/or a sixth plurality of nucleic acids encoding a population of naturally-occurring antibody light chain complementary determining region 3 (CDR3) fragments, and
inserting the fourth plurality of nucleic acids, the fifth plurality of nucleic acids, and/or the sixth plurality of nucleic acids into the CDR1 region, the CDR2 region, and the CDR3 region, respectively, of an antibody light chain variable domain gene.

### Claim 35 (depends on 33)

The method of claim 33, wherein the population of naturally-occurring antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising one or more of:
(i) a glycosylation site,
(ii) a deamidation site,
(iii) an isomerization site,
(iv) unpaired cysteine,
(v) net charge greater than 1,
(vi) a tripeptide motif containing at least two aromatic residues,
(vii) a motif that promotes aggregation,
(viii) a polyspecificity site;
(ix) a protease sensitive site,
(x) an integrin binding site,
(xi) a lysine glycation site,
(xii) a metal catalyzed fragmentation site,
(xiii) a polyspecificity aggregation site; and/or
(xiv) a streptavidin binding motif.

### Claim 36 (depends on 35)

The method of claim 35, wherein the glycosylation site of (i) comprises the motif NXS, NXT, or NXC, in which X represents any naturally-occurring amino acid residue except for proline.

### Claim 37 (depends on 35, 36)

The method of claim 35 or claim 36, wherein the deamidation site of (ii) comprises the motif of NG, NS, NT, NN, NA, NH, ND, GNF, GNY, GNT, or GNG.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the isomerization site of (iii) comprises the motif of DT, DH, DS, DG, or DD.

### Claim 39 (depends on 35, 36, 37, 38)

The method of any one of claims 35-38, wherein the tripeptide of (vi) is HYF or HWH.

### Claim 40 (depends on 35, 36, 37, 38, 39)

The method of any one of claims 35-39, wherein the motif that promotes aggregation of (vii) comprises the motif of FHW.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The method of any one of claims 35-40, wherein the polyspecificity site of (viii) comprises the motif GG, GGG, RR, VG, W, WV, WW, WWW, YY, or WXW, in which X represents any amino acid residue.

### Claim 42 (depends on 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 35-41, wherein the protease cleavage site of (ix) comprises the motif of DX, in which X is P, G, S, V, Y, F, Q, K, L, or D.

### Claim 43 (depends on 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 35-42, wherein the integrin binding site of (x) comprises RGD, RYD, LDV, or KGD.

### Claim 44 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 35-43, wherein the lysine glycation site of (xi) comprises KE, EK, or ED.

### Claim 45 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 35-44, wherein the metal catalyzed fragmentation site of (xii) comprises the motif of HS, SH, KT, HXS, or SXH, in which X represents any amino acid residue.

### Claim 46 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 35-45, wherein the polyspecificity aggregation site of (xiii) comprises a motif of X1X2X3, wherein each of X1, X2, and X3 independently is selected from the group consisting of F, I, L, V, W and Y.

### Claim 47 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 35-46, wherein the streptavidin binding motif of (xiv) comprises the motif HPQ, EPDW (SEQ ID NO: 117), PWXWL (SEQ ID NO: 118), in which X represents any amino acid residue, GDWVFI (SEQ ID NO: 119), or PWPWLG (SEQ ID NO: 120).

### Claim 48 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 35-47, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising at least two of (i)-(xiv).

### Claim 49 (depends on 48)

The method of claim 48, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising (i)-(ix).

### Claim 50 (depends on 49)

The method of claim 49, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragment is further free of members comprising one or more of (x)-(xiv).

### Claim 51 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 35-50, wherein the fourth plurality of nucleic acids, the fifth plurality of nucleic acids, and/or the sixth plurality of nucleic acids is produced by a process comprising:
(a) obtaining amino acid sequences of the light chain CDR1, CDR2, and/or CDR3 regions of a population of naturally-occurring antibodies,
(b) excluding from (a) the light chain CDR1, CDR2, and/or CDR3 amino acid sequences that comprise one or more of (i) to (xiv) to obtain liability-free light chain CDR1, CDR2, and/or CDR3 sequences, and
(c) synthesizing the fourth plurality of nucleic acids, the fifth plurality of the nucleic acids, and/or the sixth plurality of nucleic acids that encode the liability-free light chain CDR1, CDR2, and/or CDR3 regions.

### Claim 52 (depends on 51)

The method of claim 51, wherein the process for producing the fourth, fifth, and/or sixth plurality of nucleic acids further comprises, after step (c), isolating function members from the liability-free light chain CDR1, CDR2, and/or CDR3 regions.

### Claim 53 (depends on 52)

The method of claim 52, wherein the functional members of the liability-free light chain CDR1, CDR2, and/or CDR3 are isolated by expressing antibodies comprising the liability-free light chain CDR1, CDR2, and/or CDR3 regions in host cells in a manner that the antibodies are displayed on surface of the host cells, isolating the antibodies that display on the host cells, and identifying the CDR1, CDR2, and/or CDR3 regions in the displayed antibodies, which are functional members of the liability-free light chain CDR1, CDR2, and/or CDR3 regions.

### Claim 54 (depends on 53)

The method of claim 53, wherein the functional members show reduced binding to polyspecificity reagents.

### Claim 55 (depends on 54)

The method of claim 54, wherein the functional members of the liability-free heavy chain CDR1, CDR2, and/or CDR3 are isolated by expressing antibodies comprising the liability-free heavy chain CDR1, CDR2, and/or CDR3 regions in fusion with a folding reporter, which optionally is 13 lactamase or green fluorescent protein, or fragments thereof, to obtain members with improved folding.

### Claim 56 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 35-55, wherein the antibody library comprises members, each of which comprises a light chain CDR1, a light chain CDR2, and/or a light chain CDR3 that are not found in the same naturally-occurring antibody.

### Claim 57 (depends on 56)

The method of claim 56, wherein at least 50% of the members in the antibody library comprise light chain CDR1, light chain CDR2, and/or light chain CDR3 that are not found in the same naturally-occurring antibody.

### Claim 58 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 35-57, wherein the antibody light chain variable domain gene is a human antibody light chain variable domain gene, which optionally is selected from the group consisting of K1-12, K4-1, K2D-29, K3-11, K3-20, and L2-14.

### Claim 59 (depends on 58)

The method of claim 58, wherein the human antibody light chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abrilumab, mepolizumab, crenezumab, necitumumab, anifrolumab, and evoculumab.

### Claim 60 (depends on 58)

The method of claim 58, wherein the human antibody light chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abituzumab, adalimumab, alemtuzumab, alirocumab, bapineuzumab, benralizumab, brodalumab, canakinumab, certolizumab, clazakizumab, dacetuzumab, daclizumab, daratumumab, eculizumab, efalizumab, elotuzumab, epratuzumab, farletuzumab, fasinumab, ficlatuzumab, fletikumab, fresolimumab, fulranumab, gevokizumab, ibalizumab, lintuzumab, matuzumab, mavrilimumab, mogamulizumab, motavizumab, natalizumab, nivolumab, obinutuzumab, ofatumumab, olokizumab, omalizumab, onartuzumab, otelixizumab, otlertuzumab, palivizumab, panitumumab, panobacumab, pertuzumab, pinatuzumab, polatuzumab, radretumab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sifalimumab, tabalumab, tigatuzumab, tildrakizumab, tocilizumab, tovetumab, trastuzumab, vedolizumab, veltuzumab, zalutumumab, and zanolimumab.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 1-60, wherein the heavy chain CDR1, CDR2, and CDR3 fragments, the heavy chain variable domain gene, and optionally the light chain CDR1, CDR2, and CDR3 fragments, and the light chain variable domain gene are derived from naturally-occurring antibodies of a mammalian species.

### Claim 62 (depends on 61)

The method of claim 61, wherein the mammalian species is human or camelid.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 1-62, wherein the antibody library is a full-length antibody library, a Fab antibody library, a single-chain antibody library, or a single domain antibody library.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1-63, wherein the antibody library is a human antibody library.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any one of claims 1-33, wherein the antibody library is a camelid VHH antibody library.

### Claim 66

A method for preparing a human antibody light chain library, the method comprising providing (a) a first plurality of nucleic acids encoding a population of naturally-occurring antibody light chain complementary determining region 1 (CDR1) fragments, (b) a second plurality of nucleic acids encoding a population of naturally-occurring antibody light chain complementary determining region 2 (CDR2) fragments, and/or (c) a third plurality of nucleic acids encoding a population of naturally-occurring antibody light chain complementary determining region 3 (CDR3) fragments, and
inserting the first plurality of nucleic acids, the second plurality of nucleic acids, and/or the third plurality of nucleic acids into the CDR1 region, the CDR2 region, and the CDR3 region, respectively, of an antibody light chain variable domain gene, thereby producing the human antibody light chain library.

### Claim 67 (depends on 50)

The method of claim 50, wherein the population of naturally-occurring antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising one or more of:
(i) a glycosylation site,
(ii) a deamidation site,
(iii) an isomerization site,
(iv) unpaired cysteine,
(v) net charge greater than 1,
(vi) a tripeptide motif containing at least two aromatic residues,
(vii) a motif that promotes aggregation,
(viii) a polyspecificity site;
(ix) a protease sensitive site,
(x) an integrin binding site,
(xi) a lysine glycation site,
(xii) a metal catalyzed fragmentation site,
(xiii) a polyspecificity aggregation site; and
(xiv) a streptavidin binding motif.

### Claim 68 (depends on 67)

The method of claim 67, wherein the glycosylation site of (i) comprises the motif NXS, NXT, or NXC, in which X represents any naturally-occurring amino acid residue except for proline.

### Claim 69 (depends on 67, 68)

The method of claim 67 or claim 68, wherein the deamidation site of (ii) comprises the motif of NG, NS, NT, NN, NA, NH, ND, GNF, GNY, GNT, or GNG.

### Claim 70 (depends on 67, 68, 69)

The method of any one of claims 67-69, wherein the isomerization site of (iii) comprises the motif of DT, DH, DS, DG, or DD.

### Claim 71 (depends on 67, 68, 69, 70)

The method of any one of claims 67-70, wherein the tripeptide of (vi) is HYF or HWH.

### Claim 72 (depends on 67, 68, 69, 70, 71)

The method of any one of claims 67-71, wherein the motif that promotes aggregation of (vii) comprises the motif of FHW.

### Claim 73 (depends on 67, 68, 69, 70, 71, 72)

The method of any one of claims 67-72, wherein the polyspecificity site of (viii) comprises the motif GG, GGG, RR, VG, W, WV, WW, WWW, YY, or WXW, in which X represents any amino acid residue.

### Claim 74 (depends on 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 67-73, wherein the protease cleavage site of (ix) comprises the motif of DX, in which X is P, G, S, V, Y, F, Q, K, L, or D.

### Claim 75 (depends on 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 67-74, wherein the integrin binding site of (x) comprises RGD, RYD, LDV, or KGD.

### Claim 76 (depends on 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 67-74, wherein the lysine glycation site of (xi) comprises KE, EK, or ED.

### Claim 77 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 67-76, wherein the metal catalyzed fragmentation site of (xii) comprises the motif of HS, SH, KT, HXS, or SXH, in which X represents any amino acid residue.

### Claim 78 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 67-77, wherein the polyspecificity aggregation site of (xiii) comprises a motif of X1X2X3, wherein each of X1, X2, and X3 independently is selected from the group consisting of F, I, L, V, W and Y.

### Claim 79 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 67-78, wherein the streptavidin binding motif of (xiv) comprises the motif HPQ, EPDW (SEQ ID NO: 117), PWXWL (SEQ ID NO: 118), in which X represents any amino acid residue, GDWVFI (SEQ ID NO: 119), or PWPWLG (SEQ ID NO: 120).

### Claim 80 (depends on 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 67-79, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising at least two of (i)-(xiv).

### Claim 81 (depends on 80)

The method of claim 80, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising (i)-(ix).

### Claim 82 (depends on 81)

The method of claim 81, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragment is further free of members comprising one or more of (x)-(xiv).

### Claim 83 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)

The method of any one of claims 66-82, wherein the first plurality of nucleic acids, the second plurality of nucleic acids, and/or the third plurality of nucleic acids is produced by a process comprising:
(a) obtaining amino acid sequences of the light chain CDR1, CDR2, and/or CDR3 regions of a population of naturally-occurring antibodies,
(b) excluding from (a) the light chain CDR1, CDR2, and/or CDR3 amino acid sequences that comprise one or more of (i) to (xiv) to obtain liability-free light chain CDR1, CDR2, and/or CDR3 sequences, and
(c) synthesizing the first plurality of nucleic acids, the second plurality of the nucleic acids, and/or the third plurality of nucleic acids that encode the liability-free light chain CDR1, CDR2, and/or CDR3 regions.

### Claim 84 (depends on 83)

The method of claim 83, wherein the process for producing the first, second, and/or third plurality of nucleic acids further comprises, after step (c), isolating functional members from the liability-free light chain CDR1, CDR2, and/or CDR3 regions.

### Claim 85 (depends on 84)

The method of claim 84, wherein the functional members of the liability-free light chain CDR1, CDR2, and/or CDR3 are isolated by expressing antibodies comprising the liability-free light chain CDR1, CDR2, and/or CDR3 regions in host cells in a manner that the antibodies are displayed on surface of the host cells, isolating the antibodies that display on the host cells, and identifying the CDR1, CDR2, and/or CDR3 regions in the displayed antibodies, which are functional members of the liability-free light chain CDR1, CDR2, and/or CDR3 regions.

### Claim 86 (depends on 85)

The method of claim 85, wherein the functional members show reduced binding to polyspecificity reagents.

### Claim 87 (depends on 65)

The method of claim 65, wherein the functional members of the liability-free heavy chain CDR1, CDR2, and/or CDR3 are isolated by expressing antibodies comprising the liability-free heavy chain CDR1, CDR2, and/or CDR3 regions in fusion with a folding reporter, which optionally is 13 lactamase or green fluorescent protein, or fragments thereof, to obtain members with improved folding.

### Claim 88 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87)

The method of any one of claims 66-87, wherein the antibody library comprises members each of which comprises a light chain CDR1, a light chain CDR2, and/or a light chain CDR3 that are not found in the same naturally-occurring antibody.

### Claim 89 (depends on 88)

The method of claim 88, wherein at least 50% of the members in the antibody library comprise light chain CDR1, light chain CDR2, and/or light chain CDR3 that are not found in the same naturally-occurring antibody.

### Claim 90 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 66-89, wherein the antibody light chain variable domain gene is a human antibody light chain variable domain, which optionally is selected from the group consisting of K1-12, K4-1, K2D-29, K3-11, K3-20, and L2-14.

### Claim 91 (depends on 90)

The method of claim 90, wherein the human antibody light chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abrilumab, mepolizumab, crenezumab, necitumumab, anifrolumab, and evoculumab.

### Claim 92 (depends on 90)

The method of claim 90, wherein the human antibody light chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abituzumab, adalimumab, alemtuzumab, alirocumab, bapineuzumab, benralizumab, brodalumab, canakinumab, certolizumab, clazakizumab, dacetuzumab, daclizumab, daratumumab, eculizumab, efalizumab, elotuzumab, epratuzumab, farletuzumab, fasinumab, ficlatuzumab, fletikumab, fresolimumab, fulranumab, gevokizumab, ibalizumab, lintuzumab, matuzumab, mavrilimumab, mogamulizumab, motavizumab, natalizumab, nivolumab, obinutuzumab, ofatumumab, olokizumab, omalizumab, onartuzumab, otelixizumab, otlertuzumab, palivizumab, panitumumab, panobacumab, pertuzumab, pinatuzumab, polatuzumab, radretumab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sifalimumab, tabalumab, tigatuzumab, tildrakizumab, tocilizumab, tovetumab, trastuzumab, vedolizumab, veltuzumab, zalutumumab, and zanolimumab.

### Claim 93 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The method of any one of claims 66-92, wherein the light chain CDR1, CDR2, and CDR3 fragments are derived from naturally-occurring antibodies of a mammalian species.

### Claim 94 (depends on 93)

The method of claim 93, wherein the mammalian species is human.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

An antibody library, which is prepared by a method of any one of claims 1-94.

### Claim 96

An antibody library, comprising a first plurality of nucleic acids or a plurality of genetic packages comprising the nucleic acids, wherein the first plurality of nucleic acids encode a population of antibody heavy chain variable domains, which collectively comprise a population of heavy chain CDR1s, a population of heavy chain CDR2s, and/or a population of heavy chain CDR3s located at the CDR1 region, the CDR2 region, and the CDR3 region of a common antibody heavy chain variable domain gene, wherein the heavy chain CDR1s, the heavy chain CDR2s, the heavy chain CDR3s, and optionally the common antibody chain variable domain gene are derived from naturally-occurring antibodies of the same mammal species.

### Claim 97 (depends on 96)

The antibody library of claim 96, wherein the population of heavy chain CDR1s, the population of heavy chain CDR2s, and/or the population of heavy chain CDR3s is free of members comprising one or more of:
(i) a glycosylation site,
(ii) a deamidation site,
(iii) an isomerization site,
(iv) unpaired cysteine,
(v) net charge greater than 1,
(vi) a tripeptide motif containing at least two aromatic residues,
(vii) a motif that promotes aggregation,
(viii) a polyspecificity site;
(ix) a protease sensitive site,
(x) an integrin binding site,
(xi) a lysine glycation site,
(xii) a metal catalyzed fragmentation site,
(xiii) a polyspecificity aggregation site; and
(xiv) a streptavidin binding motif.

### Claim 98 (depends on 97)

The antibody library of claim 97, wherein the glycosylation site of (i) comprises the motif NXS, NXT, or NXC, in which X represents any naturally-occurring amino acid residue except for proline.

### Claim 99 (depends on 97, 98)

The antibody library of claim 97 or claim 98, wherein the deamidation site of (ii) comprises the motif of NG, NS, NT, NN, NA, NH, ND, GNF, GNY, GNT, or GNG.

### Claim 100 (depends on 97, 98, 99)

The antibody library of any one of claims 97-99, wherein the isomerization site of (iii) comprises the motif of DT, DH, DS, DG, or DD.

### Claim 101 (depends on 97, 98, 99, 100)

The antibody library of any one of claims 97-100, wherein the tripeptide of (vi) is HYF or HWH.

### Claim 102 (depends on 97, 98, 99, 100, 101)

The antibody library of any one of claims 97-101, wherein the motif that promotes aggregation of (vii) comprises the motif of FHW.

### Claim 103 (depends on 97, 98, 99, 100, 101, 102)

The antibody library of any one of claims 97-102, wherein the polyspecificity site of (viii) comprises the motif GG, GGG, RR, VG, W, WV, WW, WWW, YY, or WXW, in which X represents any amino acid residue.

### Claim 104 (depends on 97, 98, 99, 100, 101, 102, 103)

The antibody library of any one of claims 97-103, wherein the protease cleavage site of (ix) comprises the motif of DX, in which X is P, G, S, V, Y, F, Q, K, L, or D.

### Claim 105 (depends on 97, 98, 99, 100, 101, 102, 103, 104)

The antibody library of any one of claims 97-104, wherein the integrin binding site of (x) comprises RGD, RYD, LDV, or KGD.

### Claim 106 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105)

The antibody library of any one of claims 97-105, wherein the lysine glycation site of (xi) comprises KE, EK, or ED.

### Claim 107 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106)

The antibody library of any one of claims 97-106, wherein the metal catalyzed fragmentation site of (xii) comprises the motif of HS, SH, KT, HXS, or SXH, in which X represents any amino acid residue.

### Claim 108 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107)

The antibody library of any one of claims 97-107, wherein the polyspecificity aggregation site of (xiii) comprises a motif of X1X2X3, wherein each of X1, X2, and X3 independently is selected from the group consisting of F, I, L, V, W and Y.

### Claim 109 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

The antibody library of any one of claims 97-108, wherein the streptavidin binding motif of (xiv) comprises the motif HPQ, EPDW (SEQ ID NO: 117), PWXWL (SEQ ID NO: 118), in which X represents any amino acid residue, GDWVFI (SEQ ID NO: 119), or PWPWLG (SEQ ID NO: 120).

### Claim 110 (depends on 19, 97)

The antibody library of any one of claims 97-19, wherein the population of antibody heavy chain CDR1 fragments, the population of antibody heavy chain CDR2 fragments, and/or the population of antibody heavy chain CDR3 fragments is free of members comprising at least two of (i)-(xiv).

### Claim 111 (depends on 110)

The antibody library of claim 110, wherein the population of antibody heavy chain CDR1 fragments, the population of antibody heavy chain CDR2 fragments, and/or the population of antibody heavy chain CDR3 fragments is free of members comprising (i)-(ix).

### Claim 112 (depends on 111)

The antibody library of claim 111, wherein the population of antibody heavy chain CDR1 fragments, the population of antibody heavy chain CDR2 fragments, and/or the population of antibody heavy chain CDR3 fragment is further free of members comprising one or more of (x)-(xiv).

### Claim 113 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112)

The antibody library of any one of claims 97-112, wherein the population of heavy chain CDR1s, the population of heavy chain CDR2s, and/or the population of heavy chain CDR3s is further substantially free of non-functional members.

### Claim 114 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The antibody library of any one of claims 97-113, wherein the population of heavy chain CDR1s and/or the population of heavy chain CDR2s is free of members comprising one or more of (i)-(xiv) and the population of heavy chain CDR3s is derived from naturally-occurring antibodies without removal of liabilities.

### Claim 115 (depends on 114)

The antibody library of claim 114, wherein the population of heavy chain CDR3s is derived from human B cells.

### Claim 116 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115)

The antibody library of any one of claims 97-115, which comprises members having heavy chain CDR1, heavy chain CDR2, and/or heavy chain CDR3 that are not from the same naturally-occurring antibody.

### Claim 117 (depends on 116)

The antibody library of claim 116, wherein at least 50% of the members in the antibody library have heavy chain CDR1, heavy chain CDR2, and/or heavy chain CDR3 that are not from the same naturally-occurring antibody.

### Claim 118 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117)

The antibody library of any one of claims 97-117, wherein the antibody heavy chain variable region gene is a human antibody heavy chain variable region gene, which optionally is selected from the group consisting of VH1-24, VH2-70, VH3-7, VH4-30-4, VH5-51, VH1-18-VH1-69, VH3-23, VH5-10-1, VH3-9, and VH3-11.

### Claim 119 (depends on 118)

The antibody library of claim 118, wherein the human antibody heavy chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abrilumab, mepolizumab, crenezumab, necitumumab, anifrolumab, and evoculumab.

### Claim 120 (depends on 118)

The antibody library of claim 118, wherein the human antibody heavy chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abituzumab, adalimumab, alemtuzumab, alirocumab, bapineuzumab, benralizumab, brodalumab, canakinumab, certolizumab, clazakizumab, dacetuzumab, daclizumab, daratumumab, eculizumab, efalizumab, elotuzumab, epratuzumab, farletuzumab, fasinumab, ficlatuzumab, fletikumab, fresolimumab, fulranumab, gevokizumab, ibalizumab, lintuzumab, matuzumab, mavrilimumab, mogamulizumab, motavizumab, natalizumab, nivolumab, obinutuzumab, ofatumumab, olokizumab, omalizumab, onartuzumab, otelixizumab, otlertuzumab, palivizumab, panitumumab, panobacumab, pertuzumab, pinatuzumab, polatuzumab, radretumab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sifalimumab, tabalumab, tigatuzumab, tildrakizumab, tocilizumab, tovetumab, trastuzumab, vedolizumab, veltuzumab, zalutumumab, and zanolimumab.

### Claim 121 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The antibody library of any one of claims 97-120, further comprising a nucleic acid encoding a common light chain variable domain.

### Claim 122 (depends on 121)

The antibody library of claim 121, wherein the common light chain variable domain is VK3-20.

### Claim 123 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The antibody library of any one of claims 97-120, further comprising a second plurality of nucleic acids encoding a population of antibody light chain variable domains, which collectively comprise a population of light chain CDR1s, a population of light chain CDR2s, and a population of light chain CDR3s located at the CDR1 region, the CDR2 region, and the CDR3 region of a common antibody light chain variable domain gene, wherein the light chain CDR1s, CDR2s, CDR3s, and optionally the common antibody light chain domain gene are derived from naturally-occurring antibody of the same mammal species.

### Claim 124 (depends on 123)

The antibody library of claim 123, wherein the population of light chain CDR1s, the population of light chain CDR2s, and/or the population of light chain CDR3s is free of members comprising one or more of:
(i) a glycosylation site,
(ii) a deamidation site,
(iii) an isomerization site,
(iv) unpaired cysteine,
(v) net charge greater than 1,
(vi) a tripeptide motif containing at least two aromatic residues,
(vii) a motif that promotes aggregation,
(viii) a polyspecificity site;
(ix) a protease sensitive site,
(x) an integrin binding site,
(xi) a lysine glycation site,
(xii) a metal catalyzed fragmentation site,
(xiii) a polyspecificity aggregation site; and
(xiv) a streptavidin binding motif.

### Claim 125 (depends on 124)

The antibody library of claim 124, wherein the glycosylation site of (i) comprises the motif NXS, NXT, or NXC, in which X represents any naturally-occurring amino acid residue except for proline.

### Claim 126 (depends on 124, 125)

The antibody library of claim 124 or claim 125, wherein the deamidation site of (ii) comprises the motif of NG, NS, NT, NN, NA, NH, ND, GNF, GNY, GNT, or GNG.

### Claim 127 (depends on 124, 125, 126)

The antibody library of any one of claims 124-126, wherein the isomerization site of (iii) comprises the motif of DT, DH, DS, DG, or DD.

### Claim 128 (depends on 124, 125, 126, 127)

The antibody library of any one of claims 124-127, wherein the tripeptide of (vi) is HYF or HWH.

### Claim 129 (depends on 124, 125, 126, 127, 128)

The antibody library of any one of claims 124-128, wherein the motif that promotes aggregation of (vii) comprises the motif of FHW.

### Claim 130 (depends on 124, 125, 126, 127, 128, 129)

The antibody library of any one of claims 124-129, wherein the protease sensitive site of (viii) comprises the motif GG, GGG, RR, VG, W, WV, WW, WWW, YY, or WXW, in which X represents any amino acid residue.

### Claim 131 (depends on 124, 125, 126, 127, 128, 129, 130)

The antibody library of any one of claims 124-130, wherein the protease cleavage site of (ix) comprises the motif of DX, in which X is P, G, S, V, Y, F, Q, K, L, or D.

### Claim 132 (depends on 124, 125, 126, 127, 128, 129, 130, 131)

The antibody library of any one of claims 124-131, wherein the integrin binding site of (x) comprises RGD, RYD, LDV, or KGD.

### Claim 133 (depends on 124, 125, 126, 127, 128, 129, 130, 131, 132)

The antibody library of any one of claims 124-132, wherein the lysine glycation site of (xi) comprises KE, EK, or ED.

### Claim 134 (depends on 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)

The antibody library of any one of claims 124-133, wherein the metal catalyzed fragmentation site of (xii) comprises the motif of HS, SH, KT, HXS, or SXH, in which X represents any amino acid residue.

### Claim 135 (depends on 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134)

The antibody library of any one of claims 124-134, wherein the polyspecificity aggregation site of (xiii) comprises a motif of X1X2X3, wherein each of X1, X2, and X3 independently is selected from the group consisting of F, I, L, V, W and Y.

### Claim 136 (depends on 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135)

The antibody library of any one of claims 124-135, wherein the streptavidin binding motif of (xiv) comprises the motif HPQ, EPDW (SEQ ID NO: 117), PWXWL (SEQ ID NO: 118), in which X represents any amino acid residue, GDWVFI (SEQ ID NO: 119), or PWPWLG (SEQ ID NO: 120).

### Claim 137 (depends on 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136)

The antibody library of any one of claims 124-136, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising at least two of (i)-(xiv).

### Claim 138 (depends on 137)

The method of claim 137, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising (i)-(ix).

### Claim 139 (depends on 138)

The antibody library of claim 138, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragment is further free of members comprising one or more of (x)-(xiv).

### Claim 140 (depends on 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139)

The antibody library of any one of claims 123-139, which comprises members having light chain CDR1, light chain CDR2, and/or light chain CDR3 that are not from the same naturally-occurring antibody.

### Claim 141 (depends on 140)

The antibody library of claim 140, wherein at least 50% of the members in the antibody library have light chain CDR1, light chain CDR2, and/or light chain CDR3 that are not from the same naturally-occurring antibody.

### Claim 142 (depends on 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141)

The antibody library of any one of claims 123-141, wherein the antibody light chain variable domain gene is a human light chain variable gene, which optionally is selected from the group consisting of K1-12, K4-1, K2D-29, K3-11, K3-20, and L2-14.

### Claim 143 (depends on 142)

The antibody library of claim 142, wherein the human antibody light chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abrilumab, mepolizumab, crenezumab, necitumumab, anifrolumab, and evoculumab.

### Claim 144 (depends on 142)

The antibody library of claim 142, wherein the human antibody heavy chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abituzumab, adalimumab, alemtuzumab, alirocumab, bapineuzumab, benralizumab, brodalumab, canakinumab, certolizumab, clazakizumab, dacetuzumab, daclizumab, daratumumab, eculizumab, efalizumab, elotuzumab, epratuzumab, farletuzumab, fasinumab, ficlatuzumab, fletikumab, fresolimumab, fulranumab, gevokizumab, ibalizumab, lintuzumab, matuzumab, mavrilimumab, mogamulizumab, motavizumab, natalizumab, nivolumab, obinutuzumab, ofatumumab, olokizumab, omalizumab, onartuzumab, otelixizumab, otlertuzumab, palivizumab, panitumumab, panobacumab, pertuzumab, pinatuzumab, polatuzumab, radretumab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sifalimumab, tabalumab, tigatuzumab, tildrakizumab, tocilizumab, tovetumab, trastuzumab, vedolizumab, veltuzumab, zalutumumab, and zanolimumab.

### Claim 145 (depends on 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144)

The antibody library of any one of claims 96-144, wherein the heavy chain CDR1, CDR2, and CDR3 fragments, the heavy chain variable domain gene, the light chain CDR1, CDR2, and CDR3 fragments, and the light chain variable domain gene are derived from naturally-occurring antibodies of a mammalian species.

### Claim 146 (depends on 145)

The antibody library of claim 145, wherein the mammalian species is human or camelid.

### Claim 147 (depends on 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146)

The antibody library of any one of claims 96-146, wherein the antibody library is a full-length antibody library, a Fab antibody library, a single-chain antibody library, or a single domain antibody library.

### Claim 148 (depends on 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147)

The antibody library of any one of claims 96-147, wherein the antibody library is a human antibody library.

### Claim 149 (depends on 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120)

The antibody library of any one of claims 97-120, wherein the antibody library is a camelid VHH antibody library.

### Claim 150

An antibody light chain library, comprising a plurality of nucleic acids or a plurality of genetic packages comprising the nucleic acids, wherein the plurality of nucleic acids encode a population of antibody light chain variable domains, which collectively comprise a population of light chain CDR1s, a population of light chain CDR2s, and/or a population of light chain CDR3s inserted at the CDR1 region, the CDR2 region, and the CDR3 region of a common antibody light chain variable domain gene, wherein the light chain CDR1s, CDR2s, and CDR3s, and optionally the common antibody light chain variable domain gene are derived from naturally-occurring antibodies of the same mammal species.

### Claim 151 (depends on 150)

The antibody library of claim 150, wherein the population of light chain CDR1s, the population of light chain CDR2s, and/or the population of light chain CDR3s is free of members comprising one or more of:
(i) a glycosylation site,
(ii) a deamidation site,
(iii) an isomerization site,
(iv) unpaired cysteine,
(v) net charge greater than 1,
(vi) a tripeptide motif containing at least two aromatic residues,
(vii) a motif that promotes aggregation,
(viii) a polyspecificity site;
(ix) a protease sensitive site,
(x) an integrin binding site,
(xi) a lysine glycation site,
(xii) a metal catalyzed fragmentation site,
(xiii) a polyspecificity aggregation site; and
(xiv) a streptavidin binding motif.

### Claim 152 (depends on 151)

The antibody library of claim 151, wherein the glycosylation site of (i) comprises the motif NXS, NXT, or NXC, in which X represents any naturally-occurring amino acid residue except for proline.

### Claim 153 (depends on 151, 152)

The antibody library of claim 151 or claim 152, wherein the deamidation site of (ii) comprises the motif of NG, NS, NT, NN, NA, NH, ND, GNF, GNY, GNT, or GNG.

### Claim 154 (depends on 151, 152, 153)

The antibody library of any one of claims 151-153, wherein the isomerization site of (iii) comprises the motif of DT, DH, DS, DG, or DD.

### Claim 155 (depends on 151, 152, 153, 154)

The antibody library of any one of claims 151-154, wherein the tripeptide of (vi) is HYF or HWH.

### Claim 156 (depends on 151, 152, 153, 154, 155)

The antibody library of any one of claims 151-155, wherein the motif that promotes aggregation of (vii) comprises the motif of FHW.

### Claim 157 (depends on 151, 152, 153, 154, 155, 156)

The antibody library of any one of claims 151-156, wherein the polyspecificity site of (viii) comprises the motif GG, GGG, RR, VG, W, WV, WW, WWW, YY, or WXW, in which X represents any amino acid residue.

### Claim 158 (depends on 151, 152, 153, 154, 155, 156, 157)

The antibody library of any one of claims 151-157, wherein the protease cleavage site of (ix) comprises the motif of DX, in which X is P, G, S, V, Y, F, Q, K, L, or D.

### Claim 159 (depends on 151, 152, 153, 154, 155, 156, 157, 158)

The antibody library of any one of claims 151-158, wherein the integrin binding site of (x) comprises RGD, RYD, LDV, or KGD.

### Claim 160 (depends on 151, 152, 153, 154, 155, 156, 157, 158, 159)

The antibody library of any one of claims 151-159, wherein the lysine glycation site of (xi) comprises KE, EK, or ED.

### Claim 161 (depends on 151, 152, 153, 154, 155, 156, 157, 158, 159, 160)

The antibody library of any one of claims 151-160, wherein the metal catalyzed fragmentation site of (xii) comprises the motif of HS, SH, KT, HXS, or SXH, in which X represents any amino acid residue.

### Claim 162 (depends on 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161)

The antibody library of any one of claims 151-161, wherein the polyspecificity aggregation site of (xiii) comprises a motif of X1X2X3, wherein each of X1, X2, and X3 independently is selected from the group consisting of F, I, L, V, W and Y.

### Claim 163 (depends on 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162)

The antibody library of any one of claims 151-162, wherein the streptavidin binding motif of (xiv) comprises the motif HPQ, EPDW (SEQ ID NO: 117), PWXWL (SEQ ID NO: 118), in which X represents any amino acid residue, GDWVFI (SEQ ID NO: 119), or PWPWLG (SEQ ID NO: 120).

### Claim 164 (depends on 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163)

The antibody library of any one of claims 151-163, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising at least two of (i)-(xiv).

### Claim 165 (depends on 164)

The method of claim 164, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising (i)-(ix).

### Claim 166 (depends on 165)

The antibody library of claim 165, wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragment is further free of members comprising one or more of (x)-(xiv).

### Claim 167 (depends on 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166)

The antibody library of any one of claims 150-166, which comprises members having light chain CDR1, light chain CDR2, and/or light chain CDR3 that are not from the same naturally-occurring antibody.

### Claim 168 (depends on 167)

The antibody library of claim 167, wherein at least 50% of the members in the antibody library have light chain CDR1, light chain CDR2, and/or light chain CDR3 that are not from the same naturally-occurring antibody.

### Claim 169 (depends on 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168)

The antibody library of any one of claims 150-168, wherein the antibody light chain variable domain gene is a human antibody light chain variable domain gene, which optionally is selected from the group consisting of K1-12, K4-1, K2D-29, K3-11, K3-20, and L2-14.

### Claim 170 (depends on 169)

The antibody library of claim 169, wherein the human antibody light chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abrilumab, mepolizumab, crenezumab, necitumumab, anifrolumab, and evoculumab.

### Claim 171 (depends on 169)

The antibody library of claim 169, wherein the human antibody light chain variable region gene is derived from a therapeutic antibody selected from the group consisting of abituzumab, adalimumab, alemtuzumab, alirocumab, bapineuzumab, benralizumab, brodalumab, canakinumab, certolizumab, clazakizumab, dacetuzumab, daclizumab, daratumumab, eculizumab, efalizumab, elotuzumab, epratuzumab, farletuzumab, fasinumab, ficlatuzumab, fletikumab, fresolimumab, fulranumab, gevokizumab, ibalizumab, lintuzumab, matuzumab, mavrilimumab, mogamulizumab, motavizumab, natalizumab, nivolumab, obinutuzumab, ofatumumab, olokizumab, omalizumab, onartuzumab, otelixizumab, otlertuzumab, palivizumab, panitumumab, panobacumab, pertuzumab, pinatuzumab, polatuzumab, radretumab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sifalimumab, tabalumab, tigatuzumab, tildrakizumab, tocilizumab, tovetumab, trastuzumab, vedolizumab, veltuzumab, zalutumumab, and zanolimumab.

### Claim 172 (depends on 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171)

The antibody library of any one of claims 150-171, wherein the mammalian species is human.
